Why neuroleptic withdrawal in schizophrenia?
Carpenter
W T
WT
Maryland Psychiatric Research Center, Baltimore 21228.
Tamminga
C A
CA
D014150:Antipsychotic Agents / Q000008:administration & dosage / Q000009:adverse effects* / Q000627:therapeutic use; D004334:Drug Administration Schedule; D004409:Dyskinesia, Drug-Induced / Q000209:etiology / Q000517:prevention & control; D006801:Humans; D015201:Meta-Analysis as Topic; D012307:Risk Factors; D012559:Schizophrenia / Q000139:chemically induced / Q000188:drug therapy*; D013375:Substance Withdrawal Syndrome / Q000209:etiology* / Q000517:prevention & control
D014150:Antipsychotic Agents